skin cancer
FDA clears DermaSensor’s AI detection device for skin cancer
January 18, 2024Medical Communications FDA, Oncology, skin cancer
DermaSensor has announced that the US Food and Drug Administration (FDA) has granted clearance for its real-time, non-invasive skin cancer …
BMS follow-up data sees long-term survival for melanoma patients
May 24, 2021Sales and Marketing BMS, skin cancer
Bristol Myers Squibb (BMS) has announced follow-up data from their Phase III CheckMate-067 clinical trial, which demonstrated that 49% of …
FDA gives accelerated approval to AstraZeneca and Daiichi’s breast cancer drug
December 23, 2019Sales and Marketing AstraZeneca, Breast Cancer drug, Cancer, breast cancer, skin cancer
The FDA has approved the breast cancer drug Enhertu, developed by AstraZeneca and Daiichi Sankyo. José Basel, the Executive Vice …
Google AI outperforms 58 dermatologists in detecting melanoma
May 30, 2018Research and Development AI< Google, Cancer, melanoma, pharma, skin cancer
An deep learning artificial intelligence system has demonstrated its ability to outperform over 50 human dermatologists in the detection of …
Drug that induces tanning could protect against melanoma
June 16, 2017Medical Communications, Research and Development melanoma, skin cancer, sun
People will often go to extraordinary lengths to achieve tanned skin but researchers have found a potential method that does …
Skin cancer-detecting AI “on par with board-certified dermatologists”
January 27, 2017Medical Communications, Research and Development AI, Cancer, skin cancer
New research has found that artificial intelligence repurposed by researchers at Stanford University to identify skin cancer in images has …
NICE recommends Amgen’s Imlygic for advanced skin cancer
August 9, 2016Manufacturing and Production, Sales and Marketing Amgen, Imlygic, NICE, skin cancer
NICE has published its final draft guidance recommending Amgen’s Imlygic (talimogene laherparepvec) for the treatment of advanced melanoma in adults …
SMC reverses decision on Opdivo in advanced skin cancer
August 8, 2016Manufacturing and Production, Research and Development SMC, Scottish Medicines Consortium, melanoma, opdivo, skin cancer
The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended …
Nice backs two cancer drugs from Novartis
June 22, 2016Research and Development, Sales and Marketing AbbVie, Amgen, Humira, NICE, Novartis, Sanofi, lung cancer, skin cancer
The National Institute for Health and Care Excellence (Nice) has backed two drugs form Novartis (VTX: NOVN) for lung cancer …
Nice backs BMS’ combination immunotherapy Opdivo, Yervoy to treat skin cancer
June 17, 2016Medical Communications, Research and Development, Sales and Marketing BMS, NICE, oncology, opdivo, regulation, skin cancer
The National Institute for Health and Care Excellence (Nice) has backed a combination of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) and …
Novartis’ two cancer drugs get NICE backing as combination treatment for skin cancer
April 29, 2016Medical Communications NICE, Novartis, combination therapy, regulation, skin cancer
The National Institute for Health and Care Excellence (NICE) on Friday backed a combination therapy for skin cancer comprising two …
Amgen skin cancer drug Imlygic rejected by NICE
March 16, 2016Research and Development Amgen, Imlygic, NICE, melanoma, skin cancer
NICE has rejected Amgen’s drug Imlygic (talimogene laherparepvec) in draft as a treatment for advanced melanoma that has spread and …
FDA approves new uses for BMS’ Opdivo/Yervoy cancer combo
January 25, 2016Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilimumabm melanoma, nivolumab, opdivo, skin cancer
The FDA has granted Bristol Myers Squibb an expanded indication for its two-cancer drug regimen Opdivo and Yervoy, to treat …
NICE ‘yes’ for BMS skin cancer drug Opdivo
January 22, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, melanoma, nivolumab, opdivo, skin cancer
NICE has approved Bristol-Myers Squibb’s skin cancer immunotherapy Opdivo (nivolumab) in final draft guidance as monotherapy for NHS patients in England …
European approval for Amgen cancer drug Imlygic
December 18, 2015Sales and Marketing Amgen, European Commission, Imlygic, melanoma, skin cancer, t-vec, talimogene laherparepvec
The European Commission has approved the use of Amgen’s Imlygic for adults with advanced melanoma, making it the first drug …
